Floatz logo

Cixutumumab

Recurrent Non-small Cell Lung Cancer

Eli Lilly and Companymonoclonal_antibodyPhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

1206 Active assets in the Recurrent Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Cixutumumab is also rated in:

Stage IV Breast Cancer AJCC v6 and v7Dormant
BB
Indicative ·
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative ·
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →